Zogenix, Inc. Announces sumatriptan DosePro NDA Accepted for Filing by FDA

SAN DIEGO--(BUSINESS WIRE)--Zogenix, Inc. (“Zogenix”), a private, specialty pharmaceutical company, today announced that its New Drug Application (NDA) for sumatriptan DosePro™ has been accepted for filing by the U.S. Food and Drug Administration (FDA). Zogenix is seeking marketing approval from the FDA of sumatriptan DosePro for the acute treatment of migraine attacks with or without aura and cluster headache episodes. The FDA will take action on its application in late 2008.